Pfizer-BioNTech Evaluating Third COVID-19 Vaccine Dose for Variants

The new trial comes at a time when the FDA has provided guidance on navigating immunogenicity trials for vaccines designed against more transmissible SARS-CoV-2 strains.

Read the full article here

Source: Contagion Live

Categories: Infectious Disease, Latest Headlines

Tags: covid19, SARSCoV2

Tweets with this article

Contagion

A variant booster? Pfizer and BioNTech has launched a safety and immunogenicity assessment for a 3rd dose of its #COVID19 vaccine BNT162b2 to consider a booster intended to provide immunity to circulating potentially new #SARSCoV2 variants. https://t.co/gBbghaB8xx

TaiGen Completes Phase III Trials of TG-1000, Targets Influenza with Novel Antiviral Mechanism

Contagion® is a fully integrated news resource for practitioners and specialists to assist with the identification, diagnosis, treatment, and prevention of infectious diseases.

Contagion April 23, 2024

European Commission Approves Pfizer’s Antibiotic Combination for Multidrug Infections

With this approval, aztreonam-avibactam becomes the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union for treating multidrug-resistant infections, including metallo-β-lactamase-producing bacteria.

Contagion April 23, 2024

Comparative Effectiveness of Remdesivir in Early COVID-19 Treatment

Evaluating inpatient mortality for patients without supplemental oxygen at admission across different variants of concern periods with insights from Dr. Andre Kalil.

Contagion April 23, 2024

Ground Beef Recall Due to Possible E coli

US Department of Agriculture’s Food Safety and Inspection Service (FSIS) issued a public health alert over the meat.

Contagion April 22, 2024

Climate Change

Contagion® is a fully integrated news resource for practitioners and specialists to assist with the identification, diagnosis, treatment, and prevention of infectious diseases.

Contagion April 22, 2024